Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Nature Communications|May 1, 2025
Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapyZhixiang Chen, Harshil Dhruv, Xuqing Zhang, et al.
Blood|February 18, 2018
LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AMLMonica Cusan, Sheng F Cai, Helai P Mohammad, et al.
Cancer Immunology Research|February 19, 2022
Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell-Mediated Antitumor Immune ResponsesAndrew Fedoriw, Leilei Shi, Shane O'Brien, et al.
Nature Genetics|January 11, 2007
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencingJoyce E Ohm, Kelly M McGarvey, Xiaobing Yu, et al.
Nature Communications|January 20, 2019
Lsd1 as a therapeutic target in Gfi1-activated medulloblastomaCatherine Lee, Vasilisa A Rudneva, Serap Erkek, et al.
Cancer Research|September 16, 2010
Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cellsJoyce E Ohm, Prashant Mali, Leander Van Neste, et al.
Journal of Medicinal Chemistry|May 14, 2025
Discovery and Characterization of PVTX-321 as a Potent and Orally Bioavailable Estrogen Receptor Degrader for ER+/HER2- Breast CancerGuozhang Xu, Courtney G Havens, Qiaolin Deng, et al.
Cancer Discovery|May 12, 2019
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AMLCihangir Duy, Matt Teater, Francine E Garrett-Bakelman, et al.
Oncotarget|October 29, 2013
Alterations of immune response of Non-Small Cell Lung Cancer with AzacytidineJohn Wrangle, Wei Wang, Alexander Koch, et al.
Pageof 4